Results 1 to 10 of about 49,818 (236)
Effect of silencing C-erbB-2 on esophageal carcinoma cell biological behaviors by inhibiting IGF-1 pathway activation [PDF]
Journal of Cardiothoracic Surgery, 2021 Objective C-erbB-2 has been confirmed to be an oncogene that participates in cell growth, differentiation and division of tumors. We are wondered if its silenced expression can exert an anti-tumor effect. Therefore, this study is conducted to investigate
Zhigao Niu +4 more
doaj +2 more sources
Ultrasound microbubble-mediated CRISPR/Cas9 knockout of in HEC-1A cells [PDF]
Journal of International Medical Research, 2019 Objective Epidermal growth factor receptor 2 (C-erbB-2) is one of the most frequently mutated oncogenes in human tumors. We aimed to evaluate the knockout efficiency of clustered regularly interspaced short palindromic repeat (CRISPR) technology using ...
Junhong Cai +3 more
doaj +2 more sources
C-erbB-2 Expression in Primary Breast Cancer
The International Journal of Biological Markers, 1999 c-erbB-2 is an oncoprotein which is overexpressed in up to 40% of primary breast cancers. c-erbB-2 overexpression is a bad prognostic factor in patients with lymph node-positive disease.
E. Tagliabue +3 more
doaj +3 more sources
Assessment of staging, prognosis and mortality of colorectal cancer by tumor markers: receptor erbB-2 and cadherins [PDF]
Acta Cirúrgica Brasileira, 2005 PURPOSE: To evaluate the prognostic significance and correlation with staging and degree of cell differentiation of the tumoral expression of the proteins c-erbB-2 and E-cadherin, in patients with colorectal adenocarcinoma.
Jesus Eliane C. +5 more
doaj +3 more sources
Expression of MIF and c-erbB-2 in endometrial cancer. [PDF]
Mol Med Rep, 2016 The aim of the present study was to investigate the expression of c-erbB-2 and macrophage migration inhibitory factor (MIF) in endometrial cancer and to elucidate the significance of the early diagnosis and prognosis of endometrial cancer. The gene copy number of c‑erbB‑2 and MIF was characterized by reverse transcription quantitative polymerase chain ...
Xiao W +6 more
europepmc +4 more sources
Evaluation of bcl-2, bax and c-erbB-2 Levels in Chronic Otitis Patients with or without Cholesteatoma [PDF]
Turkish Archives of Otorhinolaryngology, 2015 Objective:The aim of this study was to evaluate bcl-2, bax, and c-erbB-2 expressions in primary and secondary acquired cholesteatoma and to indicate the role of apoptosis and accompanying increased cellular proliferation in the pathogenesis of ...
Özgür Işık +7 more
doaj +2 more sources
C-erbB-2 in Serum of Patients with Breast Cancer
The International Journal of Biological Markers, 1999 c-erbB-2 is an oncoprotein which is overexpressed in some breast cancers. Recently it has been established that the extracellular domain of c-erbB-2 is shed into the serum of patients with breast cancer.
L. Harris +3 more
doaj +3 more sources
c-Myb Repression of c- erbB-2 Transcription by Direct Binding to the c- erbB-2 Promoter [PDF]
Journal of Biological Chemistry, 1995 The c-myb proto-oncogene product (c-Myb) is a transcriptional activator that can bind to the specific DNA sequences. Although c-Myb also represses an artificial promoter containing the Myb binding sites, natural target genes transcriptionally repressed by c-Myb have not been identified.
G, Mizuguchi +7 more
openaire +2 more sources
Metastatic cancer cells from c-erbB-2 negative primary breast cancer maintain the original c-erbB-2/HIF1α phenotype [PDF]
Cancer Biology & Therapy, 2007 The expression of c-erbB-2 and HIF1alpha proteins is linked with an aggressive tumor phenotype and poor survival in breast cancer. In the present study we investigated whether this ominous effect is a result of c-erbB-2/HIF1alpha expressing clone appearance within the primary tumor, by examining the c-erbB-2/HIF1alpha expression status in the primary ...
Alexandra, Giatromanolaki +3 more
openaire +2 more sources
C-erbB-2 immunostaining: problems with interpretation. [PDF]
Journal of Clinical Pathology, 1994 AIMS--To assess the consistency and reproducibility of assessment of c-erbB-2 immunostaining, and to examine some of the problems relating to inter- and intraobserver variability in the documentation of positive staining; to profile the spectrum of cytoplasmic and membranous staining in a wide range of tumour types.
E W, Kay +4 more
openaire +2 more sources